- Home
- SKIN vs CNTB Comparison
SKIN vs CNTB Comparison
Compare SKIN & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKIN | CNTB |
|---|---|---|
| Founded | 1997 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.4M | 135.7M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SKIN | CNTB |
|---|---|---|
| Price | $0.82 | $2.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $2.03 | ★ $8.67 |
| AVG Volume (30 Days) | ★ 6.0M | 677.5K |
| Earning Date | 05-07-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.56 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $300,790,000.00 | $64,000.00 |
| Revenue This Year | $0.88 | N/A |
| Revenue Next Year | $4.60 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.55 | $1.23 |
| 52 Week High | $2.69 | $3.82 |
Technical Indicators
Market Signals| Indicator | SKIN | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 51.57 | 51.08 |
| Support Level | $0.81 | $2.10 |
| Resistance Level | $0.92 | $2.75 |
| Average True Range (ATR) | 0.12 | 0.22 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 30.06 | 28.47 |
Price Performance
Historical ComparisonAbout SKIN The Beauty Health Company
SkinHealth Systems Inc is a world-wide medical aesthetics company delivering an integrated ecosystem of clinically validated solutions designed to help consumers achieve superior skin health and support the success of providers. Its brands are Hydrafacial and SkinStylus.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.